Biotinylated ε-Polylysine-Cyclodextrin-Coated Mesoporous Silica Nanoparticles for Targeted pH-Responsive Baicalin Delivery Authors: Rongqiang Liao, Yi Ruan, Ke Zhang, Maoxia Liu Published: 2026 ABSTRACT IntroductionBaicalin (BAI) is a natural flavonoid with antitumor potential, but its poor water solubility and low bioavailability limit clinical use. Mesoporous silica nanoparticles are promising drug carriers due to their large surface area and tunable pore structure, yet premature drug leakage remains a key challenge.MethodsA multifunctional nanoplatform, designated as BPCD@BAI@BMSN, was constructed to enable efficient baicalin loading, pH-responsive gated release, and biotin-mediated active tumor targeting. A novel biotin-ε-polylysine-cyclodextrin (BPCD) conjugate was synthesized via EDCI/NHS coupling and characterized by NMR and GPC. Hollow mesoporous silica nanoparticles (BMSN) were prepared by the Stöber method, surface-modified with benzothiazole. The BPCD conjugate was coated onto the nanoparticle surface via cyclodextrin-benzothiazole host-guest self-assembly. The resulting nanoparticles were characterized by TEM, DLS, zeta potential, FTIR, and TGA. Drug loading, pH-responsive release, cytotoxicity against SMMC-7721 cells, cellular uptake evaluated by confocal microscopy and flow cytometry, and in vivo antitumor efficacy in nude mice were systematically evaluated.ResultsBPCD@BAI@BMSN exhibited near-spherical morphology with a particle size of approximately 200 nm, a positive zeta potential of +10 mV, a drug loading of 19.85%, and an encapsulation efficiency of 89.6%. Cumulative baicalin release reached approximately 62% at pH 5.5, whereas only about 6% was released at pH 7.4, confirming acid-triggered gated release. The blank carrier showed no significant cytotoxicity with cell viability above 95%, while drug-loaded nanoparticles exhibited enhanced cytotoxicity at pH 6.8. Biotin-functionalized nanoparticles demonstrated significantly higher cellular uptake and tumor accumulation compared to non-targeted controls. In vivo, BPCD@BAI@BMSN achieved a tumor growth inhibition rate of 72.5% compared to the control group, with no obvious toxicity to major organs observed during the 21-day treatment period.ConclusionBPCD@BAI@BMSN integrates high drug loading, pH-responsive supramolecular gating, and active tumor targeting into a single nanoplatform, offering a promising strategy for baicalin delivery with enhanced antitumor efficacy and favorable short-term biosafety. Introduction Polylysine is mainly classified into two types: α-polylysine (α-PL) and ε-polylysine (ε-PL).1,2 These two polymers have demonstrated distinct advantages and broad application prospects across multiple fields, particularly in antimicrobial materials and drug delivery systems.3 α-Polylysine is a synthetic macromolecular polymer formed by peptide bonds through the condensation of the α-amino group of L-lysine monomers with the carboxyl group of adjacent molecules. In biomedical applications, α-PL has been widely used for drug and gene delivery owing to its good biocompatibility, ease of chemical modification, and relatively high degree of branching.4 In contrast, ε-polylysine is primarily produced via microbial fermentation and is formed through polymerization between the α-carboxyl and ε-amino groups of lysine, typically consisting of 25–30 lysine residues.5 ε-PL is a naturally derived preservative known for its excellent stability and broad-spectrum antimicrobial activity,6 and it has also been developed as a carrier for drugs and genes.7 Compared with ε-PL, α-PL possesses a higher degree of branching and is more amenable to modification, which has led to its wider application in drug and gene delivery. However, it has been reported that ε-PL-based nano-drug delivery systems exhibit 1.3-fold and 2.6-fold greater anticancer efficacy than α-PL-based systems in in vivo and in vitro studies, respectively.8 Despite these advantages, PL lacks intrinsic tumor-specific targeting capability and therefore requires modification with targeting ligands. Biotin,9 hyaluronic acid,10 folic acid,11 and RGD peptides12 have been widely used to enhance the targeting ability of PL. Among these targeting ligands, biotin offers several advantageous features for tumor-targeted drug delivery: its receptor is overexpressed on the surface of various tumor cells, biotin is a small molecule with low immunogenicity and ease of conjugation, and biotin-functionalized nanocarriers have demonstrated enhanced tumor accumulation in preclinical studies.13 These properties make biotin a suitable targeting ligand for constructing actively targeted drug delivery systems. Mesoporous silica is a novel nanomaterial whose unique mesoporous structure offers significant advantages in drug delivery applications.14 Mesoporous silica features controllable pore sizes and highly ordered pore channels, enabling it to efficiently load and store drug molecules. Owing to its large specific surface area, mesoporous silica drug carriers are readily amenable to surface functionalization, allowing the introduction of targeting ligands, stimulus-responsive groups, or other bioactive molecules to achieve precise delivery and controlled release.15 This targeting capability not only improves therapeutic efficacy but also significantly reduces toxic side effects. In addition, such carriers exhibit good biocompatibility and do not induce adverse biological reactions. Therefore, mesoporous silica-based drug delivery systems hold great promise in biomedical applications such as cancer therapy,16 gene therapy,17 and vaccine delivery.18 However, the pores of unmodified mesoporous silica remain in an open state, and during drug transport, premature drug release may occur due to the lack of pore capping, which not only reduces delivery efficiency but may also cause off-target toxicity. To address this issue, modification of mesoporous silica surfaces with cationic polymers can provide multiple functions: first, they can act as “molecular gates” to cover pore openings, effectively suppressing nonspecific drug leakage and enabling gated controlled release; second, their cationic nature enhances affinity to negatively charged cell membranes via electrostatic interactions, thereby promoting cellular uptake; additionally, the polymer layer provides an ideal platform for subsequent conjugation of targeting ligands (such as biotin and folic acid), enabling the construction of multifunctional drug delivery systems with both controlled release and active targeting capabilities.19 Cyclodextrins are a class of cyclic oligosaccharides characterized by a hydrophilic exterior and a hydrophobic interior cavity, enabling them to form reversible supramolecular complexes with various guest molecules (such as azobenzene, adamantane, and ferrocene) through host-guest recognition.20 When cyclodextrins are modified onto the surface of mesoporous silica and form “cyclodextrin-guest” supramolecular complexes with guest molecules pre-attached at the pore openings, a dynamic gating barrier can be established. Under normal physiological conditions, this complex tightly seals the pores, effectively preventing premature drug release; upon application of specific stimuli (such as competitive binders, light, pH changes, or redox signals), the interaction between cyclodextrin and the guest molecule is disrupted, leading to gate opening and on-demand drug release.21 Compared with simple polymer-based physical capping, cyclodextrin-based supramolecular gating systems provide greater spatiotemporal controllability and stimulus responsiveness, offering a more flexible design strategy for constructing intelligent and precisely responsive drug delivery carriers. Specifically, the ε-polylysine-cyclodextrin combination offers several distinct advantages: the ε-polylysine backbone enhances colloidal stability and promotes cellular uptake via electrostatic interactions, while the cyclodextrin moiety provides a reversible and dynamic supramolecular gate that can be precisely controlled by pH stimuli. The pH-responsive dissociation of the cyclodextrin-benzothiazole host-guest complex is governed by the protonation-dependent conformational change of the benzothiazole guest molecule.22 Under acidic conditions (eg, pH 5.5–6.8), protonation occurs at the nitrogen atom of the benzothiazole moiety. This protonation disrupts the intramolecular hydrogen bond between the phenolic proton and the benzothiazole nitrogen—a bond that maintains the molecule’s planarity and high hydrophobicity in its neutral state. As a result, the protonated benzothiazole adopts a more hydrophilic, non-planar conformation, which significantly reduces its binding affinity for the hydrophobic cyclodextrin cavity. This reduced affinity triggers guest dissociation from the host cavity, thereby opening the supramolecular gate and enabling rapid, on-demand drug release specifically within the acidic tumor microenvironment. Based on the above design strategy, we constructed a novel mesoporous silica nanoparticle delivery system for loading Baicalin. Recent studies have shown that Baicalin exhibits antitumor activities, including inhibition of tumor cell proliferation, induction of apoptosis, and reversal of multidrug resistance; however, its poor water solubility and low bioavailability severely limit its clinical application.23,24 To overcome these limitations, we utilized the high specific surface area and ordered pore structure of mesoporous silica to achieve efficient loading of Baicalin. On this basis, through host-guest interactions between cyclodextrin and benzimidazole,25 a biotin-ε-polylysine-cyclodextrin (BPCD) conjugate was non-covalently anchored onto the surface of mesoporous silica, forming a dynamic gating barrier. While the specific BPCD tripartite conjugate described herein has not been previously reported, several related foundational systems have been established in the literature. Huh et al reported the synthesis of cyclodextrin-conjugated ε-polylysine and demonstrated their inclusion complexation behavior.26 Ma et al developed a cyclodextrin derivative containing α-polylysine dendrons for gene and drug co-delivery,27 while Liu et al further explored star-shaped cyclodextrin-α-polylysine derivatives for co-delivering docetaxel and siRNA in cancer therapy.28 More recently, a supramolecular nanoparticle system based on cyclodextrin-conjugated α-polylysine was constructed for hepatocellular carcinoma-targeted co-delivery of gene and chemotherapeutic agents.29 Meanwhile, biotin-functionalized cyclodextrin host-guest systems have also been explored for tumor-targeted drug delivery.30 Our work distinguishes itself from these earlier reports by integrating biotin targeting, an ε-polylysine backbone, and cyclodextrin-based supramolecular gating into a single nanoplatform specifically designed for pH-responsive baicalin delivery with high drug loading and active tumor targeting. We hypothesized that integrating a BPCD conjugate as a supramolecular gatekeeper onto benzothiazole-modified mesoporous silica nanoparticles (BMSN) could enable efficient pore sealing, pH-responsive cargo release, and biotin receptor-mediated active tumor targeting for enhanced baicalin delivery. The BPCD complex, non-covalently anchored onto the benzothiazole motifs, effectively seals the pore openings, preventing premature leakage; this supramolecular locking is disrupted under acidic conditions, enabling gated release. Meanwhile, the polylysine segment imparts water solubility and cell-penetrating capability, while the biotin moiety specifically recognizes overexpressed biotin receptors on tumor cells. This strategy thus capitalizes on high drug loading, non-covalent gating, and active targeting to improve baicalin delivery efficiency in antitumor therapy. Materials and Methods Materials Glycine (Gly), cyclodextrin (CD), p-toluenesulfonyl chloride, triethanolamine, ethanol, ε-polylysine (PL), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDCI), N-hydroxysuccinimide (NHS), dimethyl sulfoxide, N,N-dimethylformamide, biotin, tetraethyl orthosilicate(TEOS), ammonia solution, cetyltrimethylammonium bromide (CTAB), sodium carbonate (Na2CO3), 4-(Boc-aminomethyl)benzoic acid (BA), dichloromethane, 1-hydroxybenzotriazole (HOBt), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDAC), 2-(2-hydroxyphenyl)benzothiazole (BT), (3-glycidoxypropyl)-trimethoxysilane (GPTS), Baicalin (BAI) and Rhodamine B (RB) were purchased from Aladdin Industrial Co., Ltd. (China). The SMMC-7721 cell line was maintained in our laboratory (non‑commercial source). It was authenticated by STR profiling before use, and its use in this study was approved by the Ethics Committee of Chongqing Medical University (No. CMU2026FE379). Methods Preparation of Biotin-ε-Polylysine-Cyclodextrin (BPCD) The synthesis of Gly-CD was conducted according to procedures detailed in prior literature.31 Initially, Glycine (Gly, 1.0 g, 13.3 mmol) and mono-6-O-(p-tolylsulfonyl)-β-CD (6.0 g, 4.7 mmol), which was previously synthesized through the reaction of β-cyclodextrin with p-toluenesulfonyl chloride in aqueous solution, were dissolved in a solvent mixture comprising water (48 mL) and triethanolamine (TEA, 32 mL). The reaction mixture was subsequently heated to reflux under a nitrogen atmosphere for a duration of 24 hours. Following this, the solution was concentrated under reduced pressure to approximately 40 mL and then poured into anhydrous ethanol (300 mL), resulting in the precipitation of a fine yellow solid. This precipitate was collected via filtration, washed thoroughly with anhydrous ethanol three times, and dried under vacuum to yield a stable yellow powder. The isolated yield was determined to be 4.4 g (62.8% based on the limiting reagent). Subsequently, the synthesized Gly-CD was utilized for the preparation of ε-polylysine-cyclodextrin (PCD) conjugates. The synthesis of PCD was facilitated by the use of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDCI) and N-hydroxysuccinimide (NHS) as coupling agents. A solution of Gly-CD (6.0 g, 5.1 mmol) in a mixture of dimethyl sulfoxide (DMSO, 25 mL) and N,N-dimethylformamide (DMF, 5 mL) was prepared, and EDCI (1.1 g, 8.5 mmol) and NHS (0.6 g, 5.2 mmol) were added. The resulting solution was stirred in an ice bath at 0°C for a period of 2 hours. Meanwhile, ε-PL (0.65 g, 0.16 mmol) was dissolved in DMSO (5 mL) and stirred for 1 hour. This solution was then introduced to the Gly-CD solution, and the mixture was stirred at room temperature for 48 hours to allow for conjugation. Following this, the solution was poured into acetone (300 mL), resulting in the precipitation of a fine yellow solid. The precipitate was collected by filtration and subjected to dialysis (using a dialysis membrane with a molecular weight cutoff of 8000 g/mol) for 96 hours to remove small molecular impurities. The dialysate was then concentrated under reduced pressure and re-precipitated in acetone (100 mL). The pure PCD was further dried under vacuum at 40°C for 16 hours. The final yield was 3.1 g (46.6% based on the limiting reagent). The number of grafted cyclodextrins per PL, here defined as the degree of substitution (DS), was calculated from 1H NMR spectra using the equation DS = M/N, where M is the number of CD molecules covalently bonded to PL (determined from the integral of the anomeric H1 proton of CD at δ=5.0–5.1 ppm), and N is the number of lysine residues per chain (determined from the integral of the methylene protons of PL at δ=0.9–1.7 ppm). The average degree of polymerization of PL was determined to be 31 based on the molecular weight (Mn=3,495 g/mol). For the synthesis of biotin-ε-polylysine-cyclodextrin (BPCD) conjugate, biotin (0.5 g) was thoroughly dissolved in water (150 mL) and mixed until a homogeneous solution was obtained. Under ice-water bath conditions, EDCI and NHS were added to the solution and allowed to react for 30 minutes. Pre-synthesized PCD (20 g) was then introduced into the reaction mixture and dispersed uniformly using ultrasonic treatment. The reaction was allowed to proceed overnight under stirring to ensure complete conjugation between biotin and PCD, facilitated by EDCI and NHS. Upon completion of the reaction, the mixture was subjected to extensive dialysis using dialysis membranes with a molecular weight cutoff of 8000 Da to remove unreacted biotin, EDCI, NHS, and other small molecular impurities. Finally, the dialyzed product was lyophilized to yield the pure BPCD conjugate. Gel permeation chromatography (GPC) analysis was performed to determine the molecular weight and polydispersity of PL and BPCD. The analysis was conducted using an aqueous mobile phase consisting of 0.01% sulfuric acid at a flow rate of 0.8 mL/min. Separation was achieved on a SEC column (300 × 7.8 mm, 100 Å, 3 μm) with the column temperature maintained at 40°C and an injection volume of 20 μL. A refractive index detector was used for signal acquisition. Molecular weight calibration was performed using polyethylene glycol standards. The number-average molecular weight (Mn), weight-average molecular weight (Mw), and polydispersity index (PDI=Mw/Mn) were calculated from the GPC chromatograms. Preparation of MSN0 A standardized template approach was employed to synthesize mesoporous silica nanoparticles (MSN0).32 Silica nanoparticles were initially synthesized using the Stöber method. Specifically, tetraethyl orthosilicate (TEOS, 3 mL) was introduced into a solution containing deionized water (8 mL), ethanol (100 mL), and ammonia solution (4 mL). This reaction mixture was then agitated for 6 hours at 37°C to facilitate the formation of SiO2. Following this, the resultant SiO2 and 1200 mg of cetyltrimethylammonium bromide (CTAB) were introduced into a blend of water (220 mL) and ethanol (10 mL). After 30 minutes of vigorous stirring, 1.075 mL of TEOS was added dropwise, and the resultant solution was continuously stirred overnight at 37°C. Subsequently, the synthesized nanoparticles were isolated via centrifugation and rinsed thoroughly with deionized water. To remove the solid silica core, the nanoparticles were redispersed in 120 mL of an aqueous solution of sodium carbonate (Na2CO3) at a concentration of 0.4 M and etched for 2 hours at 55°C. Finally, MSN0 were obtained by eliminating the CTAB micelles from the mesopores through repeated washing with a concentrated solution of HCl/ethanol (volume ratio 1:10) under sonication. Preparation of 2-(Benzo[D]thiazol-2-Yl)phenyl 4-Aminobenzoate (BB) In a 150 mL round-bottom flask, 1.00 g of 4-(Boc-aminomethyl)benzoic acid (BA) was accurately weighed and dissolved in 150 mL of dichloromethane under magnetic stirring. Subsequently, 300 mg of 1-hydroxybenzotriazole (HOBt) and 850 mg of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDAC) were added to the reaction mixture, which was stirred for 20 minutes. An additional 500 mg of 2-(2-hydroxyphenyl)benzothiazole (BT) and 900 μL of Et3N were introduced, and the reaction was stirred for 48 hours. The organic phase was then dried over anhydrous Na2SO4, filtered, and sequentially washed three times with 40 mL portions of saturated NaHCO3, NH4Cl, and NaCl solutions. The solvent was removed by rotary evaporation, and the crude product was purified by column chromatography to yield the Boc-BB derivative. Subsequently, 400 mg of Boc-BB was weighed and added to a mixture of 50 mL of CF3CO2H and CH2Cl2 in a round-bottom flask. The reaction mixture was stirred for 5 hours, and the solvent was removed by rotary evaporation. The resulting yellow oil was dissolved in a mixture of 30 mL of CH2Cl2 and 80 mL of saturated aqueous NaHCO3. The product was extracted with CH2Cl2, washed with deionized water, dried over anhydrous Na2SO4, filtered, and further concentrated by rotary evaporation. The resultant solid was recrystallized from toluene/n-hexane to obtain pure BB. Preparation of BMSN For the synthesis of BMSN nanoparticles, a 20 mL toluene solution containing 100 mg of MSN0 and 0.1 mL of (3-glycidoxypropyl)-trimethoxysilane (GPTS) was stirred for 5 hours. The solid phase was separated by centrifugation, rinsed repeatedly with deionized water, and freeze-dried. In a separate flask, 90 mg of BB was dissolved in 15 mL of toluene, and 50 mg of the previously prepared solid phase nanoparticles were added. The mixture was agitated at 60°C for 24 hours. Following centrifugation, the solid product was rinsed twice with deionized water and freeze-dried to yield the final BMSN nanoparticles. Preparation of the BAI-Loaded Nanoparticles (BPCD@BAI@BMSN) To encapsulate the drug, a round-bottomed flask was utilized, into which 20 mL of absolute ethanol, 50 mg of BAI, and 100 mg of BMSN were added. The resultant mixture was stirred at room temperature for a duration of 24 hours to facilitate thorough mixing and reaction. Subsequently, the solution was centrifuged to isolate the BAI-loaded BMSN particles. These particles underwent washing with deionized water and were then lyophilized to yield the final product, a yellow solid designated as BAI@BMSN. To construct the nanovalves, the synthesized BPCD was coated onto the surface of BAI@BMSN via the self-assembly interaction between cyclodextrin and benzothiazole. This coating process involved mixing 10 mg of BAI@BMSN with 5 mg of BPCD in 5 mL of deionized water and stirring the mixture continuously at room temperature for 12 hours. Following this step, the solid product was obtained through centrifugation and lyophilization. The resultant product, designated as BPCD@BAI@BMSN, represents a drug-loaded and nanoparticle-capped system. Determination of Drug Loading and Entrapment Efficiency An BAI solution (2 mg/mL) was prepared using absolute ethanol as the solvent. BMSN was added to a sample vial, followed by the addition of 20 mL of the BAI solution (2 mg/mL). The mixture was shaken at room temperature for adsorption for 3 h. Subsequently, BPCD solution was added, and the system was further shaken for another 3 h. The mixture was then centrifuged at 5000 r/min for 10 min. The concentration of BAI in the supernatant was determined by UV spectroscopy. The equilibrium adsorption capacity (Q, mg/g), drug loading rate (%), and entrapment efficiency (%) were calculated according to Equations (1), (2), and (3), respectively.(1)\documentclass[12pt]{minimal} \usepackage{wasysym} \usepackage[substack]{amsmath} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage[mathscr]{eucal} \usepackage{mathrsfs} \DeclareFontFamily{T1}{linotext}{} \DeclareFontShape{T1}{linotext}{m}{n} {linotext }{} \DeclareSymbolFont{linotext}{T1}{linotext}{m}{n} \DeclareSymbolFontAlphabet{\mathLINOTEXT}{linotext} \begin{document}$${Q_e} = {{\left({{C_0} - {C_e}} \right)V} \over m}$$\end{document} (2)\documentclass[12pt]{minimal} \usepackage{wasysym} \usepackage[substack]{amsmath} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage[mathscr]{eucal} \usepackage{mathrsfs} \DeclareFontFamily{T1}{linotext}{} \DeclareFontShape{T1}{linotext}{m}{n} {linotext }{} \DeclareSymbolFont{linotext}{T1}{linotext}{m}{n} \DeclareSymbolFontAlphabet{\mathLINOTEXT}{linotext} \begin{document}$$Drug\,loading\,rate = {{({m_0} - {m_1})} \over {{m_2}}} \times 100\mathrm{\%}$$\end{document} (3)\documentclass[12pt]{minimal} \usepackage{wasysym} \usepackage[substack]{amsmath} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage[mathscr]{eucal} \usepackage{mathrsfs} \DeclareFontFamily{T1}{linotext}{} \DeclareFontShape{T1}{linotext}{m}{n} {linotext }{} \DeclareSymbolFont{linotext}{T1}{linotext}{m}{n} \DeclareSymbolFontAlphabet{\mathLINOTEXT}{linotext} \begin{document}$$Entrapment\,efficiency = {{({m_0} - {m_1})} \over {{m_0}}} \times 100\mathrm{\%}$$\end{document} Where: C0 is the initial concentration of BAI (mg/L); Ce is the residual concentration of BAI (mg/L); V is the volume of the solution (L); m is the mass of BMSN and BPCD (g); m0 is the initial mass of BAI added (g); m1 is the residual mass of BAI in the solution (g); and m2 is the mass of BMSN and BPCD after loading BAI (g). pH-Controlled Drug Release Analysis Stock solutions with different pH values were prepared. 5 mg of dried BPCD@BAI@BMSN was placed into a 50 mL Erlenmeyer flask, followed by the addition of 25 mL of the corresponding pH solution. The flask was then incubated in a thermostatic water bath shaker at 37 °C to allow drug release. At predetermined time intervals, 3 mL of the release medium was withdrawn for BAI concentration analysis, and an equal volume (3 mL) of fresh solution with the same pH was replenished. All release measurements were performed in triplicate. The concentration of BAI in the release medium was determined by UV-Vis spectrophotometry at 335 nm. A standard calibration curve was constructed using baicalin solutions in the concentration range of 0.5–50 μg/mL in the corresponding pH buffer. The calibration curve exhibited excellent linearity with a correlation coefficient (R2) of 0.999. To exclude interference from formulation components, blank samples of the release medium were used as references. The cumulative release percentage (CRP) of the drug was calculated according to Equation (4):(4)\documentclass[12pt]{minimal} \usepackage{wasysym} \usepackage[substack]{amsmath} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage[mathscr]{eucal} \usepackage{mathrsfs} \DeclareFontFamily{T1}{linotext}{} \DeclareFontShape{T1}{linotext}{m}{n} {linotext }{} \DeclareSymbolFont{linotext}{T1}{linotext}{m}{n} \DeclareSymbolFontAlphabet{\mathLINOTEXT}{linotext} \begin{document}$$CRP = {{{V_e}\mathop \sum \nolimits_1^{n - 1} {c_i} + {V_0}{c_n}} \over {{m_{BAI}}}} \times 100\mathrm{\%}$$\end{document} Where: Ve is the volume of each withdrawn sample (L); V0 is the total volume of the release medium (L); ci is the BAI concentration in the i-th withdrawn sample (mg/L); mBAI is the total mass of BAI loaded in the drug delivery system (mg); and n is the number of sampling times. Characterization Assays Fourier Transform Infrared (FT-IR) spectroscopy was conducted within the wavelength range of 400–4000 cm−1 utilizing a TENSOR-27 spectrometer manufactured by Bruker (Germany), employing the KBr pellet method. The 1H nuclear magnetic resonance (NMR) spectrum was acquired using an Avance III ultra-shield NMR spectrometer from Bruker, operating at 500 MHz. The ZEN3600 Zetasizer from Malvern Instruments was employed to determine size distribution and zeta potential in deionized water. The shape and average diameter of the synthesized nanoparticles (NPs) were investigated using a transmission electron microscope (TEM) (JEM-2010F, USA), operated at an acceleration voltage of 200 kV. In vitro Cytotoxicity Analysis SMMC-7721 cells were utilized to evaluate the cytotoxic effects of BAI, BPCD@BMSN, and BPCD@BAI@BMSN. A total of 5,000 cells were plated overnight at 37°C in a humidified atmosphere containing 5% CO2, in 96-well plates filled with 200 microliters (μL) of DMEM media supplemented with 10% fetal bovine serum (FBS) and 1% antibiotics [100 units per milliliter (U/mL) of penicillin and 100 milligrams per milliliter (mg/mL) of streptomycin]. The cells were incubated with varying quantities of BAI and BPCD@BAI@BMSN, each containing equivalent BAI concentrations, for 48 hours under the aforementioned conditions. To ascertain the safety of the carrier, a parallel experiment was conducted using blank BPCD@BMSN nanoparticles. Cell viability was assessed through the MTT assay. Briefly, 100 μL of cell culture from the 96-well plates was mixed with 20 μL of MTT stock solution. The mixture was incubated for 4 hours at 37°C, followed by centrifugation to remove and discard the MTT-containing medium. To solubilize the resultant formazan precipitate, 150 μL of dimethyl sulfoxide (DMSO) was added. The absorbance was then measured at 490 nm using a spectrometer. Cell viability was assessed through the MTT assay. All experiments were performed in triplicate wells and repeated at least three times independently. Cellular Uptake Assays of BPCD@RB@BMSN Confocal microscopy was used to investigate the internalization of BPCD@BMSN. into SMMC-7721 cells. Given that BAI lacks intrinsic fluorescent properties, Rhodamine B (RB) was employed as a fluorescent surrogate to assess the cellular uptake of the nanoparticles. This approach assumes that the uptake and release behavior of RB-loaded nanoparticles is representative of BAI-loaded nanoparticles, as both molecules are encapsulated within the mesoporous silica core and the nanoparticle surface properties remain unchanged, which is a widely adopted strategy for evaluating the cellular uptake of mesoporous silica-based drug delivery systems.33 Cells, plated on glass coverslips at a density of 1.0 million cells per coverslip, were incubated overnight. Following this, the cells were exposed to BPCD@RB@BMSN for 4 hours under standard culture conditions. After fixing the cells with 4% paraformaldehyde, they were thoroughly washed with phosphate-buffered saline (PBS). The internalization of BPCD@RB@BMSN was visualized using a confocal microscope (Olympus FV 3000, Japan), with RB excited at a wavelength (λex) of 560 nanometers (nm). For quantitative analysis, SMMC-7721 cells were seeded in 6-well plates at a density of 2×105 cells per well and incubated overnight. Cells were then treated with the same three groups as described above for 4 hours. After treatment, cells were washed twice with PBS, trypsinized, and resuspended in 500 μL of PBS. Fluorescence intensity was measured using a flow cytometer, and at least 10,000 events were acquired for each sample. Data were analyzed using FlowJo software, and mean fluorescence intensity was calculated for quantitative comparison. Animals and Tumor Model All animal procedures were conducted in strict compliance with the National Research Council’s Guide for the Care and Use of Laboratory Animals and were approved by the University’s Animal Care and Laboratory Animal Research Committee. Male BALB/c nude mice (6–8 weeks old) were obtained from Chengdu Yaokang Biotechnology Co., Ltd. and housed under specific pathogen-free conditions with a 12 h light/dark cycle at 24 °C, with free access to water and standard chow. For tumor inoculation, SMMC-7721 cells (1×106 cells per mouse) suspended in 200 μL of phosphate-buffered saline (PBS) were subcutaneously injected into the right armpit. Tumor growth was monitored every 3 days using vernier calipers, and tumor volume was calculated as π/6× (Rmax × Rmin2). In vivo Antitumor Efficacy Evaluation Nude mice with tumors reaching approximately 50–100 mm3 were randomly divided into three groups (n=3 per group): (1) control group (normal saline), (2) PCD@BAI@BMSN group, and (3) BPCD@BAI@BMSN group. On days 7, 9, and 11 post-inoculation, BPCD@BAI@BMSN or PCD@BAI@BMSN was administered via tail vein injection at a dose equivalent to 100 mg/kg of baicalin, while the control group received normal saline alone. At the end of the 21-day observation period, mice were deeply anesthetized with isoflurane and euthanized by cervical dislocation. Tumor tissues and major organs (heart, liver, spleen, lungs, and kidneys) were harvested, fixed in 4% paraformaldehyde, embedded in paraffin, and sectioned for histological and immunohistochemical analysis. In vivo Fluorescence Imaging To evaluate the tumor-targeting ability of the nanoparticles, nude mice were randomly divided into two groups (n=3 per group): (1) PCD@DIR@BMSN group (non-targeted) and (2) BPCD@DIR@BMSN group (biotin-targeted). DIR-loaded nanoparticles were prepared following the same protocol as BAI-loaded nanoparticles. Each mouse received a single tail vein injection of DIR-loaded nanoparticles at a dose of 100 μg/kg DIR. At 2, 12, 24, and 48 h post-injection, mice were anesthetized with isoflurane and imaged using an in vivo imaging system (excitation: 745 nm; emission: 820 nm). This approach has been widely employed to track the in vivo fate of mesoporous silica-based drug delivery systems.34 Statistical Analysis All data are presented as mean ± SD from at least three independent experiments. Statistical analyses were performed employing independent sample t-tests for comparisons between two groups and one-way ANOVA for comparisons among three or more groups. A p-value < 0.05 was considered statistically significant. Significance levels: *p < 0.05, **p < 0.01, ***p < 0.001; ns, not significant. All analyses were performed using GraphPad Prism 8.0. Results and Discussion Preparation of BPCD@BAI@BMSN The BPCD was synthesized using biotin, Gly-CD, and ε-polylysine (ε-PL) with catalytic amounts of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDCI) and N-hydroxysuccinimide (NHS) to produce an amide-based pendant polymer. The synthesis process is illustrated in Figure 1a. The degree of substitution (DS), defined as the number of CD molecules grafted per ε-PL chain, was determined by 1H NMR integration. The 1H NMR spectrum (Figure 2a) of BPCD showed a distinctive peak for the H1 proton of cyclodextrin (CD) at approximately 5 ppm. The DS was calculated by comparing the integral values of the H1 protons of CD with those of the methylene protons of ε-PL, which resonate in the range of 0.9–1.7 ppm. The results indicated an average attachment of 10 CD molecules per ε-PL backbone. Additionally, a characteristic peak for biotin was observed at 4.0–4.5 ppm. Gel permeation chromatography analysis shows that the average molecular weight of BPCD (15694 g/mol) is greater than that of PL (3320 g/mol), with PDI values of 1.367 for BPCD and 1.153 for PL. The synthesis of BB was carried out according to the procedure outlined in Figure 1b, and the NMR results of BB are shown in Figure 2b. Subsequently, BB was covalently attached to the surface of mesoporous silica nanoparticles (MSN0). Finally, using the self-assembly interaction between BB and CD, BPCD was assembled onto the outermost layer of BMSN. The detailed steps are illustrated in Figure 1c. Figure 1Schematic illustration of the fabrication of BPCD@BAI@BMSN. (a) Synthesis of BPCD. (b) Preparation of BB from BA and BT. (c) Assembly of BPCD and BB onto MSN0 surfaces to construct the final BPCD@BAI@BMSN nanocomposite.Three sub-images (labeled a, b, and c) illustrate the preparation process of BPCD@BAI@BMSN. Image a, Gly-CD and PL form PCD, which then reacts with biotin to produce BPCD. Image b shows BA and BT forming BB. Image c shows MSN0 being converted into BMSN via GPTS and BB, followed by further formation of BPCD@BAI@BMSN.Three part reaction scheme for BPCD@BAI@BMSN: BPCD synthesis, BB synthesis, BPCD@BAI@BMSN assembly. Figure 2The 1H NMR spectra. (a) Spectrum of BPCD. (b) Spectrum of free BB. (c) Spectrum of the assembled BPCD@BB complex.Three line graphs (labeled a, b, and c) show H NMR spectra, with the x-axis representing chemical shift, ranging from 8.5 to 0.0. Image a is the H NMR spectrum of BPCD. The peak at approximately 5.0 ppm is labeled as H1 of CD, the region from 4.5 to 4.0 ppm is labeled as H of Bio, and the bracketed region from 1.7 to 0.9 ppm is labeled as –CH2CH2CH2– of PL. Image b is the H NMR spectrum of BB, with signals concentrated between 8.5 and 7.0 ppm. Image c is the H NMR spectrum of BPCD assembled with BB, in which all peaks of the assembled BB exhibited chemical shifts.The NMR chemical shift changes of free BB before and after assembly with BPCD. Schematic illustration of the fabrication of BPCD@BAI@BMSN. (a) Synthesis of BPCD. (b) Preparation of BB from BA and BT. (c) Assembly of BPCD and BB onto MSN0 surfaces to construct the final BPCD@BAI@BMSN nanocomposite. The 1H NMR spectra. (a) Spectrum of BPCD. (b) Spectrum of free BB. (c) Spectrum of the assembled BPCD@BB complex. To verify that the BB modified on the MSN0 surface could interact with BPCD via non-covalent bonds, we conducted in-depth NMR analysis. NMR analysis is a well-established tool for evaluating non-covalent interactions between cyclodextrins and guest molecules. Encapsulation of a guest molecule within the CD cavity typically results in a shift in the proton peaks of the guest molecule. Upon mixing BB with BPCD, the NMR spectrum showed significant shifts in all the proton peaks of BB (Figure 2c). This finding underscores the ability of BPCD to coat the BMSN surface through non-covalent interactions. Characterization Analysis The morphology of the synthesized BMSN and BPCD@BMSN was characterized by transmission electron microscopy (TEM). In the TEM images (Figure 3a and b), BMSN and BPCD@BMSN exhibited a highly ordered and uniformly distributed porous structure. Specifically, BMSN and BPCD@BMSN displayed a near-spherical shape, with particle sizes mainly ranging from 150 to 200 nm, demonstrating good size uniformity. Upon magnification, fine channel structures were observed throughout each BMSN particle. These mesopores not only increased the material’s specific surface area but also provided effective channels for drug transport. The TEM magnified images revealed some changes in the morphology of BPCD@BMSN compared to BMSN. In particular, the previously visible mesopores almost completely disappeared in the polymer-covered samples, indicating that BPCD successfully filled the pore spaces on the surface of BMSN. This change not only resulted in a decrease in porosity but also suggested that the polymer layer effectively covered the surface of the mesoporous silica, allowing for drug encapsulation within the mesopores. Figure 3Characterization analysis. (a) TEM image of BMSN. (b) TEM image of BPCD@BMSN. (c) Particle size distribution. (d) Zeta potential measurements. (e) Nitrogen adsorption-desorption isotherms and pore size distribution of BMSN. (f) Nitrogen adsorption-desorption isotherms and pore size distribution of BPCD@BMSN. (g) Fourier-transform infrared spectra of BAI, BPCD@BMSN and BPCD@BAI@BMSN. (h) Thermogravimetric analysis curves of BAI, BPCD@BMSN and BPCD@BAI@BMSN.Image a and Image b are TEM micrographs showing the morphologies of BMSN particles and BPCD@BMSN particles. Image c is a particle size distribution plot. The curves for BMSN and BPCD@BMSN peak at approximately 100 nm, with BPCD@BMSN being slightly larger. Image d is a zeta potential plot; BMSN peaks at about -10 mV, and BPCD@BMSN peaks at about +15 mV. Image e and Image f are pore size distribution and adsorption plots for BMSN and BPCD@BMSN; the pore sizes of both BMSN and BPCD@BMSN are in the range of 2–4 nm. Image g shows FTIR spectra, displaying the spectra of BAI, BPCD@BMSN, and BPCD@BAI@BMSN. Image h shows thermogravimetric analysis curves with temperatures ranging from 40 to 320 degrees centigrade, displaying the curves for BAI, BPCD@BMSN, and BPCD@BAI@BMSN.Multi-panel characterization figure comparing BMSN and BPCD@BMSN by TEM, size, zeta, pores, FTIR, TGA. Characterization analysis. (a) TEM image of BMSN. (b) TEM image of BPCD@BMSN. (c) Particle size distribution. (d) Zeta potential measurements. (e) Nitrogen adsorption-desorption isotherms and pore size distribution of BMSN. (f) Nitrogen adsorption-desorption isotherms and pore size distribution of BPCD@BMSN. (g) Fourier-transform infrared spectra of BAI, BPCD@BMSN and BPCD@BAI@BMSN. (h) Thermogravimetric analysis curves of BAI, BPCD@BMSN and BPCD@BAI@BMSN. To gain a more precise understanding of the impact of BPCD on the properties of BMSN nanoparticles, particle size and zeta potential analyses were subsequently performed. The particle size analysis (Figure 3c) showed that the average particle size of BMSN was approximately 160 nm, while that of BPCD@BMSN was around 200 nm. The increase in particle size of BPCD@BMSN compared to BMSN can be attributed to the formation of a polymer layer via the self-assembly of cyclodextrin with BB. The zeta potential analysis (Figure 3d) showed that the ζ-potential of BMSN was −8 mV, while the ζ-potential of BPCD@BMSN was +10 mV. This change indicates that the polymer coating not only altered the surface properties of BMSN particles but also enhanced their interaction with cell membranes by introducing positive charges. Since cell membranes are typically negatively charged, positively charged nanoparticles can more easily adsorb onto the cell membrane via electrostatic interactions and subsequently enter the cells through endocytosis. Therefore, BPCD@BMSN nanoparticles, due to their positive charge, may exhibit higher cellular uptake efficiency and better bioavailability, which is significant for drug delivery. To further investigate the structural characteristics of BMSN and BPCD@BMSN, nitrogen adsorption-desorption analysis was conducted (Figure 3e and f). From the nitrogen adsorption-desorption isotherms, both BMSN and BPCD@BMSN exhibited type IV isotherms according to the IUPAC classification. This characteristic indicates that both nanomaterials possess a well-ordered mesoporous structure, which is consistent with the TEM observations. Type IV isotherms are typically associated with the adsorption behavior of mesoporous materials, characterized by a gradual increase in adsorption at low relative pressures and a sharp increase near a relative pressure of 1 due to capillary condensation within the mesopores. This feature further confirms the mesoporous structure of both BMSN and BPCD@BMSN. By analyzing the nitrogen adsorption-desorption isotherms, the specific surface areas of the two nanomaterials were calculated. The specific surface area of BMSN was 642.06 m2/g, while that of BPCD@BMSN slightly decreased to 539.27 m2/g. This change may be due to the partial blockage or occupation of mesopores by the BPCD coating, which reduced the surface area available for nitrogen adsorption. Pore size analysis showed that the pore size of BMSN was primarily around 4.2 nm, while that of BPCD@BMSN decreased to 2.7 nm. This change further validates the modification of the mesoporous structure by the polymer layer. The reduction in pore size may result from the deposition and filling of the polymer on the mesopore surfaces, causing a shrinkage of the pore size. However, it is noteworthy that despite the reduction in pore size, BPCD@BMSN still retained the characteristic mesoporous structure, which could provide potential advantages for its application in drug delivery. FTIR spectroscopy was used to investigate the structure of BAI, BPCD@BMSN, and BPCD@BAI@BMSN (Figure 3g). The FTIR spectrum of BAI showed characteristic absorption bands at 3030–2800 cm−1, 1667 cm−1, 1600–1000 cm−1, and 800–500 cm−1, corresponding to the stretching vibrations of aromatic hydrogen on the benzene ring, the skeletal stretching vibrations of the benzene ring, and the out-of-plane bending vibration of C-H in monosubstituted benzene. Additionally, a stretching vibration peak of the carbonyl group (C=O) was observed at 1728 cm−1. The FTIR spectrum of BPCD@BMSN showed a broad absorption peak near 3450 cm−1, attributed to the O-H stretching vibration from the hydroxyl groups on the framework and adsorbed water. A strong absorption band at 1080 cm−1 was assigned to the Si-O-Si stretching vibration, and peaks at 945 cm−1 and 485 cm−1 were attributed to Si-O stretching vibrations, characteristic of silica. These results confirm the formation of a Si-O network structure. The FTIR spectrum of BPCD@BAI@BMSN displayed all the characteristic peaks of both BAI and BPCD@BMSN, indicating that BAI was successfully loaded into the BMSN. TGA analysis was performed to assess the thermal stability of BAI, BPCD@BMSN, and BPCD@BAI@BMSN (Figure 3h). As shown in the figure, the mass of BAI gradually decreased with increasing temperature from room temperature to 120°C, which could be attributed to the volatilization of water molecules, with a weight loss of 7.12%. As the temperature further increased, BAI experienced slow weight loss, indicating gradual degradation, with a weight loss of 8.23%. At temperatures above 273°C, BAI underwent rapid weight loss and was completely degraded. Similarly, BPCD@BMSN showed a weight loss of 7.01% as water molecules began to evaporate between room temperature and 120°C. When the temperature reached 292°C, BPCD@BMSN exhibited a weight loss of 8.23%, primarily due to the degradation of BPCD. Upon exceeding 292°C, BPCD@BMSN rapidly degraded. For BPCD@BAI@BMSN, a weight loss of 4.01% was observed between room temperature and 120°C due to water evaporation. When the temperature reached 293°C, BPCD@BAI@BMSN experienced slow weight loss of 18.94%, mainly due to the gradual degradation of both BPCD and BAI. At temperatures above 293°C, BPCD@BAI@BMSN underwent rapid degradation. The TGA analysis demonstrated that BPCD@BAI@BMSN exhibits good thermal stability, and further confirmed that BAI was successfully loaded into BPCD@BMSN. Drug Loading and Controlled Release BAI exhibits the highest UV absorbance at 335 nm. Based on the Beer-Lambert law, the drug loading rate of BPCD@BAI@BMSN was calculated to be 19.85%, and the encapsulation efficiency was 89.6%, according to the standard calibration curve of BAI and the relevant calculation formula. In a recent study, Xiao et al developed a diselenide-bridged mesoporous silica nanoplatform for BAI delivery with a drug loading of 11.12%, an encapsulation efficiency of 93.5%, and a particle size of approximately 60 nm.35 The drug release profile of BPCD@BAI@BMSN at different pH values (5.5, 6.8, 7.4) is shown in Figure 4a. As observed, the cumulative drug release rate first increases gradually over time, then stabilizes. At pH 5.5, the highest cumulative drug release rate was approximately 62%, and the initial release rate was significantly higher compared to pH 6.8 and 7.4. After 12 hours, the highest cumulative release rates were 54% and 6% at pH 6.8 and 7.4, respectively. This difference can be attributed to the pH-sensitive molecular switch on the surface of the nanoparticle carrier (Figure 4b). Under acidic conditions, the benzothiazole group is protonated, causing it to detach from the cyclodextrin cavity, which in turn opens the molecular switch. Furthermore, the surface-modified lipid bonds are also pH-sensitive. As the pH decreases, the lipid bonds break, causing BPCD to detach from the BMSN surface. Therefore, at pH 5.5, the release rate is faster, and the cumulative drug release rate is higher. Over time, as the concentration gradient of the drug inside and outside the carrier decreases, the release rate slows down. As BPCD is completely detached, the release process gradually reaches equilibrium. The incomplete release of baicalin, with approximately 38% remaining entrapped at pH 5.5, may be attributed to a primary factor. A portion of BAI may be strongly adsorbed onto the internal silica mesoporous walls via non-covalent interactions such as hydrogen bonding with the silica surface, which are not readily disrupted by pH changes.36 To verify the gating function of the BPCD coating, we evaluated the release behavior of BAI@BMSN without the BPCD gatekeeper under the same pH conditions. As shown in Figure 4c, BAI@BMSN displayed rapid drug release, reaching approximately 64% cumulative release within 1.5 hours at both pH 5.5 and pH 7.4. The release kinetics showed no significant difference between the two pH conditions, confirming that bare MSN lacks pH-responsive gating capability and releases cargo rapidly regardless of environmental pH. In contrast, BPCD@BAI@BMSN released only about 6% at pH 7.4 over 24 hours while achieving a similar 62% release at pH 5.5. This comparison clearly demonstrates that the BPCD coating functions as an effective molecular gate that seals pore openings at physiological pH and prevents premature drug leakage. In summary, the drug delivery system BPCD@BAI@BMSN exhibits good pH responsiveness. Figure 4pH-responsive release behavior of nanoparticles. (a) Cumulative release profiles at different pH conditions of BPCD@BAI@BMSN. (b) Schematic illustration of the proposed pH-controlled release mechanism. (c) Cumulative release profiles at different pH conditions of BAI@BMSN.Image a: Line graph showing BAI release profiles in nanoparticles. Time (h) on x-axis, Released (%) on y-axis. At pH 5.5, curve rises steeply, plateauing near 62%. At pH 6.8, curve rises gradually, plateauing near 55%. At pH 7.4, curve remains flat near 10% over 12 hours. Image b: . Schematic of the assembled BPCD, BAI, and BMSN, represented as a sphere with chemical groups. The release mechanism of BAI at pH 5.5, showing that the molecular gate opens under acidic conditions. Image c: Line graph showing BAI release profiles in BMSN. Time (h) on x-axis, Released (%) on y-axis. Both pH 7.4 and pH 5.5 curves rise rapidly, plateauing near 65% by 2 hours, with no significant difference between pH conditions.Graphs show pH-dependent drug release and gate mechanism of BAI in nanoparticles. pH-responsive release behavior of nanoparticles. (a) Cumulative release profiles at different pH conditions of BPCD@BAI@BMSN. (b) Schematic illustration of the proposed pH-controlled release mechanism. (c) Cumulative release profiles at different pH conditions of BAI@BMSN. In vitro Cytotoxicity Analysis The IC50 of free BAI against SMMC-7721 cells was 71.00 μg/mL at pH 7.4 and 68.62 μg/mL at pH 6.8. The cytotoxicity of BPCD@BAI@BMSN nanoparticles against SMMC-7721 cells and the pH-dependent release effect were evaluated using the MTT assay. The results in Figure 5 show the cell viability of three experimental groups under pH 7.4 and pH 6.8 environments. In these experiments, cells were treated with free BAI or BPCD@BAI@BMSN at an equivalent baicalin concentration of 40 μg/mL. As shown in the figure, the blank carrier BPCD@BMSN nanoparticles exhibited negligible cytotoxicity with cell viability above 95% at both pH conditions, confirming the safety of the carrier. BPCD@BAI@BMSN showed approximately 86% cell viability at pH 7.4, while at pH 6.8 the cell viability decreased significantly to 65%. Free BAI showed comparable cytotoxicity at both pH conditions with approximately 65% cell viability, indicating that baicalin itself is not pH-dependent. The fact that BPCD@BAI@BMSN at pH 6.8 exhibited similar cytotoxicity to free BAI at the same baicalin concentration confirms that baicalin was substantially released from the nanocarrier under acidic conditions. Figure 5Cell viability of SMMC-7721 cells after 48 h incubation with free BAI (40 μg/mL), BPCD@BAI@BMSN (containing 40 μg/mL baicalin, equivalent to approximately 200 μg/mL nanoparticles), and blank BPCD@BMSN (200 μg/mL nanoparticles) at pH 7.4 and pH 6.8. Data are presented as mean ± SD (n = 3). *p < 0.05.Bar graph: cell viability for BPCD @BMSN, BPCD@BAI @BMSN and BAI at pH 7.4 & 6.8. Cell viability of SMMC-7721 cells after 48 h incubation with free BAI (40 μg/mL), BPCD@BAI@BMSN (containing 40 μg/mL baicalin, equivalent to approximately 200 μg/mL nanoparticles), and blank BPCD@BMSN (200 μg/mL nanoparticles) at pH 7.4 and pH 6.8. Data are presented as mean ± SD (n = 3). *p < 0.05. In vitro Cell Targeting Study To verify the targeting capability of the BPCD@BMSN nanoparticle carrier, fluorescence microscopy was used for analysis. Since BAI is not fluorescent, we used Rhodamine B (RB) as a substitute. This approach is feasible and has been validated in previous studies by other researchers.33 As shown in the Figure 6, under the white light channel, a small amount of PCD@RB@BMSN can be seen entering some cells (indicated by yellow arrows). In the red fluorescence channel, the red fluorescence of RB is clearly visible. Additionally, DIO and DAPI staining were used to visualize the cell membranes and nuclei, respectively. In the white light channel, a significantly higher amount of BPCD@RB@BMSN entered the cells compared to PCD@RB@BMSN, which can be attributed to the presence of the biotin (Bio) targeting ligand in the BPCD@RB@BMSN nanoparticles. This targeting ligand helps promote the uptake of BPCD@RB@BMSN into cells. In the red fluorescence channel, the red fluorescence of RB is more intense in the BPCD@RB@BMSN-treated cells. When BPCD@RB@BMSN was added to cells in a pH 6.5 environment, the white light channel showed the highest quantity of BPCD@RB@BMSN particles, and the red fluorescence was the strongest. This is because the Bio targeting ligand facilitates the entry of BPCD@RB@BMSN into cells, and in the acidic environment, it further leads to the release of RB from BPCD@RB@BMSN. Flow cytometry analysis results further confirmed the observations made by fluorescence microscopy. Figure 6Characterization of nanocarrier internalization by fluorescence microscopy and flow cytometry. (a) Fluorescence microscopy images of cells treated with nanocarriers; (b) flow cytometric quantification of cellular fluorescence intensity. The yellow arrows indicate BPCD@RB@BMSN. Data are presented as mean ± SD (n = 3). **p < 0.01, ****p < 0.0001.Fluorescence images and flow cytometry analysis of cells after uptake of the nanocarriers.. Characterization of nanocarrier internalization by fluorescence microscopy and flow cytometry. (a) Fluorescence microscopy images of cells treated with nanocarriers; (b) flow cytometric quantification of cellular fluorescence intensity. The yellow arrows indicate BPCD@RB@BMSN. Data are presented as mean ± SD (n = 3). **p < 0.01, ****p < 0.0001. In vivo Tumor Targeting Evaluation To evaluate the in vivo active targeting capability of the nanoparticle carrier, we established a subcutaneous tumor model using SMMC-7721 tumor-bearing nude mice. The nude mice were randomly divided into two groups: PCD@DIR@BMSN (non-targeted group) and BPCD@DIR@BMSN (targeted group). The fluorescence distribution in the tumor area was dynamically monitored using an in vivo imaging system at 2 hours, 12 hours, 24 hours, and 48 hours after injection (Figure 7). The results showed that at 2 hours post-injection, neither the targeted nor non-targeted groups displayed significant specific fluorescence signals in the tumor region. Fluorescence was mainly distributed in the liver and kidneys of the mice. By 12 hours, the targeted group exhibited clear and well-defined fluorescence signals in the tumor region, while fluorescence in the liver remained strong. In contrast, the non-targeted group still showed no fluorescence in the tumor region, with fluorescence primarily in the liver. This indicates that the biotin ligand-receptor recognition effectively promoted the accumulation of the nanoparticle carrier in the tumor area. At 24 hours post-injection, the fluorescence intensity in the tumor of the targeted group reached its peak for the entire observation period, with the tumor boundary clearly visible. Fluorescence in the liver area decreased compared to previous time points. In the non-targeted group, weak fluorescence appeared in the tumor region, and fluorescence in the liver also decreased, indicating that active targeting further promoted the sustained accumulation of the nanoparticle carrier at the tumor site. In the non-targeted group, weak fluorescence appeared in the tumor region, and fluorescence in the liver also decreased. The weak tumor accumulation of non-targeted nanoparticles could be attributed to the enhanced permeability and retention (EPR) effect, a passive targeting mechanism by which nanoparticles preferentially accumulate in solid tumor tissues through leaky tumor vasculature and impaired lymphatic drainage.37 However, the EPR effect is highly dependent on tumor type, vascularization, and nanoparticle physicochemical properties, and its efficiency is often limited. At 48 hours, the tumor fluorescence in the targeted group slightly weakened but remained at a high level, while fluorescence in the liver completely disappeared. In the non-targeted group, fluorescence in both the tumor and liver regions had disappeared. These results suggest that BPCD@DIR@BMSN nanoparticles, after being taken up by the tumor cells, can achieve long-lasting retention at the tumor site. Additionally, 48 hours post-injection, no fluorescence was observed in the heart, liver, spleen, lungs, or kidneys of either the targeted or non-targeted groups when the mice were euthanized. However, strong fluorescence was present only in the tumor tissue of the targeted group. In conclusion, these dynamic imaging results demonstrate that biotin modification enables BPCD@DIR@BMSN to initiate tumor-specific accumulation at 12 hours, peak at 24 hours, and maintain at least until 48 hours. This process significantly outperforms the non-targeted control group, exhibiting efficient, specific, and sustained active tumor targeting capability. Figure 7In vivo fluorescence intensity of subcutaneous tumors in mice at different time points, and ex vivo fluorescence images of heart, liver, spleen, lung, kidney, and tumor tissues after sacrifice.The diagram consists of two rows of images depicting fluorescence in mice at different time points and in various organs. The top row represents the non-targeted group labeled as PCD at DIR at BMSN without biotin, while the bottom row represents the targeted group labeled as BPCD at DIR at BMSN including biotin. Each row contains images at 2 hours, 12 hours, 24 hours and 48 hours post-injection, followed by ex vivo images of organs at 48 hours. In the non-targeted group, fluorescence is primarily observed in the liver and kidneys at 2 hours, with minimal tumor fluorescence. By 12 hours, liver fluorescence remains strong and tumor fluorescence is still not significant. At 24 hours, weak tumor fluorescence appears and liver fluorescence decreases. At 48 hours, fluorescence in the liver disappears and weak tumor fluorescence persists. In the targeted group, fluorescence is initially seen in the liver and kidneys at 2 hours. By 12 hours, strong fluorescence is observed in the tumor region, with liver fluorescence still present. At 24 hours, tumor fluorescence peaks and liver fluorescence decreases. At 48 hours, tumor fluorescence remains high, while liver fluorescence disappears. The ex vivo images show fluorescence in the heart, liver, spleen, lung, kidney and tumor, with the targeted group showing strong tumor fluorescence. A color scale on the right indicates fluorescence intensity, ranging from low to high.A diagram showing fluorescence in mice with and without biotin nanoparticles at various time points and organs after sacrifice. In vivo fluorescence intensity of subcutaneous tumors in mice at different time points, and ex vivo fluorescence images of heart, liver, spleen, lung, kidney, and tumor tissues after sacrifice. In vivo Efficacy and Safety Evaluation To evaluate the in vivo targeting and antitumor efficacy of BPCD@BAI@BMSN, a subcutaneous SMMC-7721 tumor-bearing nude mouse model was established. The mice were randomly divided into three groups: control group (saline), non-targeted group (PCD@BAI@BMSN), and targeted group (BPCD@BAI@BMSN). The drug administration schedule and sacrifice time points are shown in Figure 8a. The tumor growth curves are presented in Figure 8b. The control group showed continuous and rapid tumor growth throughout the observation period. The non-targeted PCD@BAI@BMSN group exhibited partial inhibition of tumor growth, with a slower increase in tumor volume. Notably, the targeted BPCD@BAI@BMSN group demonstrated the most potent antitumor effect, with tumor volumes consistently smaller than the non-targeted group. The tumor growth inhibition rates were calculated to be 39.3% for the PCD@BAI@BMSN group and 72.5% for the BPCD@BAI@BMSN group compared to the control group. These results demonstrate that biotin-mediated active targeting significantly enhances the in vivo antitumor efficacy of the nanocarrier system. Figure 8In vivo antitumor efficacy and histopathological evaluation. (a) Schematic illustration of the animal dosing regimen and sacrifice time points. (b) tumor volume growth curves over the experimental period. (c) representative photographs of excised tumors from each group after sacrifice. (d) immunohistochemical staining images of tumor sections, showing cellular morphology and marker expression.The schematic illustration shows the animal dosing regimen for tumor treatment. Tumor cell implantation occurs on Day 0, followed by BPCD@BAI@BMSN intravenous injections on Days 7, 9 and 11, with sacrifice on Day 21. A line graph displays tumor volume growth over 21 days, with the x-axis labeled ′days′ and the y-axis labeled ′Tumor volume (mm superscript 3)′. The control group shows rapid growth, while PCD@BAI@BMSN (no biotin) and BPCD@BAI@BMSN (including biotin) groups show reduced growth. Photographs of excised tumors from each group are shown. Histological images include H&E, TUNEL and Ki-67 staining for control, PCD@BAI@BMSN (no biotin) and BPCD@BAI@BMSN (including biotin) groups, illustrating cellular morphology and marker expression.A schematic of tumor treatment in mice with growth curves and histological images. In vivo antitumor efficacy and histopathological evaluation. (a) Schematic illustration of the animal dosing regimen and sacrifice time points. (b) tumor volume growth curves over the experimental period. (c) representative photographs of excised tumors from each group after sacrifice. (d) immunohistochemical staining images of tumor sections, showing cellular morphology and marker expression. Previous studies have reported tumor inhibition rates for baicalin nanocarrier systems in various tumor models. Mi et al developed a folic acid-decorated ZIF-8 nanosystem loaded with baicalin for breast cancer therapy, where free baicalin showed negligible antitumor efficacy with tumor growth curves almost overlapping with the PBS control group, while the targeted formulation significantly inhibited tumor proliferation.38 Li et al reported a folate-targeted pH-sensitive albumin nanoparticle loaded with baicalin for enhancing tamoxifen efficacy in estrogen receptor alpha-positive breast cancer, achieving a tumor suppression rate of 82.06% in combination with tamoxifen.39 In the present study, the BPCD@BAI@BMSN system achieved a tumor growth inhibition rate of 72.5%, which is attributed to the synergistic effects of biotin-mediated active targeting and pH-responsive drug release that enhance tumor accumulation and intracellular drug delivery. After 21 days of treatment, the mice were sacrificed, and tumor tissues were excised, weighed, and photographed (Figure 8c). The average tumor weight in the control group was the highest, followed by the PCD@BAI@BMSN group, while the BPCD@BAI@BMSN group had the lowest tumor weight. These results suggest that PCD@BAI@BMSN itself possesses some anti-tumor activity, but the BPCD@BAI@BMSN group significantly enhanced its anti-tumor effect, confirming that the strategy effectively increased the nanoparticle accumulation at the tumor site. Tumor tissue immunohistochemistry results are shown in Figure 8d. H&E staining revealed that in the control group, tumor cells were densely packed with large, dark-staining nuclei, prominent nuclear atypia, and frequent mitotic figures, with no apparent necrotic areas. In the PCD@BAI@BMSN group, scattered necrotic foci and nuclear pyknosis were observed. The BPCD@BAI@BMSN group exhibited large areas of necrosis, with nuclear pyknosis, fragmentation, and dissolution, and blurred cell boundaries, indicating the most severe degree of necrosis. Ki-67 immunohistochemical staining showed that the positive cell rate in the BPCD@BAI@BMSN group was significantly lower than that in the PCD@BAI@BMSN and control groups, indicating that BPCD@BAI@BMSN effectively inhibited tumor cell proliferation. TUNEL staining revealed the highest number of apoptotic cells in the BPCD@BAI@BMSN group, followed by the PCD@BAI@BMSN group, while the control group showed few apoptotic cells, confirming that BPCD@BAI@BMSN significantly induced tumor cell apoptosis. The enhanced apoptosis and reduced proliferation in the BPCD@BAI@BMSN group are consistent with baicalin’s known molecular mechanisms. BAI binds to the STAT3 N-terminal domain, disrupts JAK2-STAT3 interaction, and inhibits STAT3 phosphorylation at Tyr705.23 Additionally, BAI suppresses the PI3K/Akt/mTOR, ERK1/2, and β-catenin pathways via ROS accumulation, decreasing c-Myc, cyclin A2, cyclin E1, and Cdk2 expression, which induces S-phase arrest and mitochondria-mediated apoptosis.40 The sustained intracellular delivery of BAI from BPCD@BAI@BMSN likely prolongs these effects, contributing to its enhanced antitumor efficacy. After the treatment was completed, the mice were sacrificed, and their hearts, livers, spleens, lungs, and kidneys were collected for H&E staining to observe histological changes under an optical microscope. As shown in Figure 9, no notable morphological abnormalities were observed in any of the examined organs across all groups (control, PCD@BAI@BMSN, and BPCD@BAI@BMSN). Specifically, the heart exhibited well-preserved myocardial architecture without apparent degeneration or necrosis; the liver showed largely preserved lobular architecture with orderly arranged hepatic cords; the spleen maintained an overall preserved tissue architecture without obvious structural abnormalities; the lungs displayed well-preserved alveolar architecture without apparent alveolar wall thickening or exudative changes; and the kidneys showed preserved glomerular and tubular structures without evident inflammatory cell infiltration. Overall, no apparent histopathological differences were observed between the treated groups and the control group. These results indicate that BPCD@BAI@BMSN, at the therapeutic dose, did not induce evident histopathological abnormalities in the major organs examined after 21 days of treatment, thereby supporting its favourable in vivo biosafety profile over the treatment period. Figure 9Immunohistochemical staining of mouse tissues (heart, liver, spleen, lung and kidney), showing representative images from each organ.Immunohistochemical staining of heart, liver, spleen, lung, kidney. Immunohistochemical staining of mouse tissues (heart, liver, spleen, lung and kidney), showing representative images from each organ. Limitations Despite the promising findings, several limitations should be acknowledged. First, Rhodamine B and DIR were used as fluorescent surrogates for baicalin in cellular uptake and in vivo imaging studies. Although this approach is widely adopted for mesoporous silica-based systems, it does not fully reflect the actual biodistribution and intracellular fate of the therapeutic payload, and the release kinetics of the surrogate may differ from that of baicalin. Second, the enhanced tumor accumulation of biotin-functionalized nanoparticles is attributed to biotin receptor-mediated active targeting; however, direct evidence such as receptor blocking or competitive inhibition assays was not performed in this study, and the contribution of the enhanced permeability and retention (EPR) effect cannot be completely ruled out. Third, the 21-day observation period is sufficient for short-term efficacy and safety assessment, but it is inadequate to evaluate long-term chronic toxicity, tissue persistence, immunogenicity, or biodegradation of the silica framework, which are critical for clinical translation. Fourth, approximately 38% of the loaded baicalin remained entrapped within the nanocarrier even at pH 5.5, likely due to strong non-covalent adsorption to the silica walls; further optimization of surface chemistry or pore structure is needed to achieve complete cargo release. Fifth, the in vivo antitumor study lacked a free baicalin group and a blank carrier group, which limits the direct comparison of the nanocarrier’s superiority over conventional drug administration and the inherent antitumor activity of the carrier itself. Finally, the relatively small sample size (n=3 per group for imaging and efficacy studies) reduces the statistical power, and therefore the results should be interpreted as exploratory. Future work will address these issues by performing competitive targeting assays, extending the observation period, optimizing drug release efficiency, and conducting larger-scale preclinical studies. Conclusion In summary, a biotin-ε-polylysine-cyclodextrin conjugate (BPCD) was synthesized and applied to construct a multifunctional mesoporous silica-based drug delivery system, BPCD@BAI@BMSN. The cyclodextrin-benzothiazole supramolecular gating mechanism effectively suppressed premature drug leakage at physiological pH while enabling rapid BAI release under acidic tumor microenvironment conditions. Biotin-mediated active targeting significantly enhanced tumor-specific accumulation and intracellular uptake compared to non-targeted controls, translating into superior tumor growth inhibition in SMMC-7721 tumor-bearing nude mice. Histological examination confirmed pronounced tumor necrosis and apoptosis with no detectable toxicity to major organs. These results demonstrate that BPCD@BAI@BMSN offers an effective strategy for improving the antitumor delivery of baicalin, with no obvious toxicity to major organs observed within the 21-day treatment period, suggesting its potential as a pH-responsive and actively targeted nanomedicine.